US-China Biosecurity Cooperation Is Possible: Screen DNA Synthesis Orders

ChinaTalk · rss · 2026-09-08

ChinaTalk argues nucleic acid synthesis screening is the most workable US-China cooperation point against AI-enabled bio risk:

Cross-spectrum consensus: Altman, Amodei, Hassabis and others signed a June letter urging mandatory screening of DNA/RNA orders — because even AI-designed pathogens must pass through physical synthesis providers, one of the few chokepoints.
US status: The Trump administration scrapped the Biden-era screening framework promising something stronger, then let it slip; Cotton-Klobuchar and Pfluger-Houlahan bills are moving.
Why China matters: China hosts 34% of global DNA synthesis providers, runs a more open-source AI ecosystem with weaker safeguards, and unilateral US screening would just reroute orders. IBBIS maps 700+ providers across 81 countries.
China's incentives: BGI and GenScript already participate in IGSC voluntary screening; weaker model-level safeguards give China more reason to strengthen downstream chokepoints; near-KYC coverage aids customer verification; the Biosecurity Law offers legal hooks.
Limits: benchtop synthesizers, split orders and overseas suppliers remain gaps, but cost and scale constraints keep them from being "pathogen printers," and screening barely slows biotech. The piece urges putting it on the US-China AI talks agenda.

More from Safety